Medicines | Horizonscan geneesmiddelen

Lisdexamfetamine ^IND Melatonine Molindone

Brexucabtagene autoleucel ^IND Dasatinib ^G Obecabtagene autoleucel Ponatinib ^IND

Arimoclomol ^IND Sodium phenylbutyrate/tauroursodeoxycholic acid

Azacitidine Cytarabine / daunorubicin (liposomaal) Decitabine/cedazuridine Eprenetapopt Glasdegib Imetelstat Iomab-B Venetoclax ^IND

Axicabtagene ciloleucel ^IND Crizotinib ^IND

Ibrutinib

Mantle cell lymphoma (MCL), 1L. ^IND Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation

Lisocabtagene maraleucel Loncastuximab tesirine Pirtobrutinib Polatuzumab vedotin ^IND Tafasitamab Zamtocabtagene autoleucel Zanubrutinib ^IND

Dabigatran ^G Proteïne C ^IND Ravulizumab ^IND

Dupilumab ^IND Masitinib Tezepelumab

Ceftobiprole Ceftolozane / tazobactam ^IND Citric acid / lactic acid / potassium bitartrate ^IND Clindamycin Dalbavancine ^IND Delafloxacin ^IND Durlobactam / sulbactam Eravacycline SER 109 Tebipenem

Avelumab ^IND

Durvalumab

Neo-adjuvant durvalumab met chemotherapie en adjuvant durvalumab voor behandeling in patiënten met spier invasieve blaaskanker. ^IND Unresectable locally advanced or metastatic urothelial cancer in combination with tremelimumab and chemotherapy ^IND

Enfortumab vedotin Inbakicept Nivolumab ^IND

Etrolizumab ^IND Filgotinib ^IND Mirikizumab Ozanimod ^IND Risankizumab ^IND Teduglutide ^IND

Upadacitinib

Rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. ^IND Moderately to Severely Active Crohns disease ^IND

Vedolizumab ^IND

Autologous glioma tumor cell lysates

Abemaciclib ^IND Amcenestrant Balixafortide Neratinib ^IND Olaparib ^IND Paclitaxel

Palbociclib

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery. ^IND Patients with HR+/HER2- invasive early breast cancer in combination with standard adjuvant endocrine therapy. ^IND

Pembrolizumab

Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. ^IND KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence. ^IND

Sacituzumab govitecan Tesetaxel

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ^IND Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy in the metastatic setting and has progressed on, and would no longer benefit from, endocrine therapy. ^IND

Trastuzumab duocarmazine Tucatinib

Acalabrutinib

Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).

Duvelisib Ibrutinib ^IND Pirtobrutinib ^IND Ublituximab

Zanubrutinib

Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) ^IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy ^IND

Asciminib

APN01 Anakinra ^IND Baricitinib ^IND Casirivimab / imdevimab ^IND Casirivimab/imdevimab Molnupiravir PF-07321332 / ritonavir Regdanvimab ^IND

Remdesivir

Extension of indication to include adults who do not require invasive mechanical ventilation at start of treatment. • In adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment). ^IND Treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment ^IND

Sotrovimab

Tixagevimab / cilgavimab

The prevention of COVID-19 in adults. Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen. ^IND

Tocilizumab ^IND

Cemiplimab ^IND Durvalumab ^IND Lifileucel

Nivolumab ^IND Tegafur / gimeracil / oteracil ^IND

Elexacaftor / tezacaftor / ivacaftor

Kaftrio is indicated in a combination regimen with ivacaftor 150mg tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene ^IND

Ivacaftor ^IND

Aducanumab

Bupropion/dextromethorphan Esketamine ^IND Zuranolone

Bexagliflozine Dapagliflozine ^IND Dasiglucagon Exenatide ^IND

Finerenon

Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes ^IND

Insulin lispro ^G Polyethylene glycol loxenatide Sotagliflozine ^IND Teplizumab Tirzepatide

Golodirsen Vamorolone

Brivaracetam ^IND Cannabidiol ^IND Cenobamaat Fenfluramine ^IND Ganaxolone Lacosamide ^IND

Aflibercept ^IND Avacincaptad pegol Brolucizumab ^IND

Faricimab

Treatment of neovascular (wet) age-related macular degeneration (nAMD). Treatment of visual impairment due to diabetic macular oedema (DME).

Lenadogene nolparvovec Pegcetacoplan ^IND Perfluorohexyloctane Phentolamine

Ranibizumab

Wet age-related macular degeneration (AMD). ^BS Wet age-related macular degeneration (AMD). ^BS Treatment of neovascular age-related macular degeneration (AMD)

Reproxalap Sepofarsen Timrepigene emparvovec

Ibrexafungerp ^IND Oteseconazole

Posaconazol

Extension of indication to include primary treatment of invasive aspergillosis in adults and adolescents from 13 years of age for Noxafil gastroresistant tablet and concentrate for solution for infusion. ^IND Extension of indication to include primary treatment of invasive aspergillosis in paediatric patients from 2 years of age weighing more than 40kg and adults for Noxafil gastroresistant tablet and concentrate for solution for infusion. Noxafil gastro-resistant tablets and solution are indicated for use in the treatment of the following fungal infections: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products. ^IND

Rezafungin

Atazanavir / cobicistat Doravirine / lamivudine / tenofovirdisoproxil ^IND Fostemsavir Lenacapavir Raltegravir ^BS

Pembrolizumab ^IND Tislelizumab ^IND

Atogepant Dihydroergotamine Eptinezumab Lasmiditan Meloxicam / rizatriptan Rimegepant

Emicizumab ^IND Eptacog alfa (activated) ^BS Eptacog beta (activated) Etranacogene dezaparvovec FLT180a Valoctocogene roxaparvovec

Axicabtagene ciloleucel ^IND Copanlisib Hypericin Lacutamab Mosunetuzumab Parsaclisib Umbralisib

Baloxavir marboxil ^IND Fluticasone propionate

Avelumab ^IND Cabozantinib ^IND Lenvatinib ^IND

Pembrolizumab

Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). ^IND Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. ^IND

Tivozanib ^IND

Bempedoic acid Evinacumab Evolocumab ^IND Inclisiran

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC). ^IND

Lenvatinib ^IND Pembrolizumab ^IND Pemigatinib Tremelimumab ^IND

Maralixibat ^IND Obeticholic acid Seladelpar

Adagrasib Amivantamab

Atezolizumab

Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK‑positive NSCLC ^IND Extension of indication to include adjuvant treatment of non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TC) for Tecentriq as monotherapy ^IND

Avelumab ^IND Capmatinib

Cemiplimab

Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. ^IND Extension of indication to include LIBTAYO in combination with platinum‐based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations, independen of PD-L1 expression. ^IND

Durvalumab

Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. ^IND Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. ^IND 1L advanced NSCLC ^IND Completely resected NSCLC ^IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND

Ensartinib Lenvatinib ^IND Lorlatinib ^IND Lurbinectedin Mobocertinib Nivolumab ^IND OSE-2101 Osimertinib ^IND Pembrolizumab ^IND Pralsetinib Selpercatinib ^IND Sintilimab Sotorasib Tepotinib Tislelizumab Toripalimab Trastuzumab deruxtecan ^IND Tremelimumab Trilaciclib

Ambrisentan ^IND Benralizumab ^IND Gefapixant

Mepolizumab

Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala ^IND Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab).

Pirfenidone ^IND

Nivolumab ^IND

Arimoclomol Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene Avalglucosidase alfa Bardoxolone Methyl Betaine ^G Cipaglucosidase alfa / miglustat Elamipretide Fexapotide Fezolinetant Fosdenopterin Hydrocortison Leriglitazone Levoketoconazole Liraglutide ^IND Lonafarnib Migalastat ^IND Octreotide Olenasufligene relduparvovec Olipudase alfa Palovarotene Pegunigalsidase alfa Reloxaliase Sapropterin ^G Somatrogon Sparsentan

Belantamab mafodotin ^IND Carfilzomib ^IND Ciltacabtagene autoleucel

Daratumumab

Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). ^IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). ^IND Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. ^IND In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy. ^IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. ^IND Smouldering multipel myeloom. ^IND

Elranatamab Idecabtagene vicleucel

Isatuximab

Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ^IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. ^IND

Ixazomib ^IND Melphalan flufenamide ^IND Pomalidomide ^IND Selinexor ^IND Teclistimab Thalidomide ^G Venetoclax ^IND Zevorcabtagene autoleucel

Dimethyl fumarate

Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). ^IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G

Diroximel fumarate Ofatumumab

Teriflunomide

Aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis. ^IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). ^G

Ublituximab

Amifampridine ^G Bidridistrogene xeboparvovec Daxibotulinumtoxine A Deoxythymidine/deoxycytidine Di-deuterated ethyl linoleate Efgartigimod Ravulizumab ^IND Sugammadex ^G

Momelotinib Navitoclax Ropeginterferon alfa-2b

Selumetinib Surufatinib

Cannabidiol gel/intradermaal Clazosentan Eculizumab ^IND Eladocagene exuparvovec Inebilizumab Remimazolam Rozanolixizumab Satralizumab Tiratricol Vutrisiran Zilucoplan

Afamitresgene autoleucel Dostarlimab Durvalumab ^IND Efbemalenograstim alfa Erdafitinib Futibatinib Glucarpidase Infigratinib Ivosidenib ^IND Jodium (131I) omburtamab

Lenvatinib

Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation ^IND Advanced or Recurrent Endometrial Cancer (1L) in combination with pembrolizumab. ^IND

Lipegfilgrastim ^IND NY-ESO-1 autologous engineered TCR-T cells

Nivolumab

Opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy ^IND Extension of indication to include in combination with fluoropyrimidineand platinum-based combination chemotherapy the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) for OPDIVO. ^IND

Pembrolizumab

Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. ^IND Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1. ^IND Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10. ^IND Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. ^IND

Selinexor ^IND Sodium thiosulfate Tebentafusp

Adrenaline Arachis hypogaea (pinda) allergenen (pleister) Avacopan Avapritinib ^IND

Baricitinib

Systemic lupus erythematosus ^IND Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant. ^IND

Berotralstat Budesonide modified released capsule ^IND Canakinumab ^IND Coacillium topical Dupilumab ^IND FCR 001 Icatibant ^G Mavorixafor OTL 103 RP-L201 Sizavaleucel Sutimlimab Voclosporin Vonoprazan

Eltrombopag ^IND Zanubrutinib

Allogenic immunomodulatory progenitor cells Angiotensin II Apabetalon Dapagliflozine ^IND Emiplacel Empagliflozine ^IND Etripamil Fibrinogen / Thrombin ^IND Icosapent ethyl Macitentan ^IND Macitentan / tadalafil Mavacamten Omecamtiv mecarbil Rexlemestrocel-L Rilonacept Sotagliflozine ^IND Tadalafil ^IND Tafamidis ^IND Udenafil Vericiguat

Abaloparatide Burosumab ^IND Corifollitropin alfa ^IND Drospirenon / estetrol, monohydraat Ospemifene Semaglutide Setmelanotide ^IND

Crizanlizumab Daprodustat Eculizumab ^BS Efgartigimod Eptacog alfa ^IND Exagamglogene autotemcel Horse anti-human T lymphocyte immunoglobulin Luspatercept ^IND Mepolizumab ^IND Mitapivat Pegcetacoplan RP-L102

Ravulizumab

Behandeling van volwassen en pediatrische patiënten met een lichaamsgewicht van 10 kg of meer met paroxismale nachtelijke hemoglobinurie (PNH): - bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit. - bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab Uitbreiding van de behandeling naar pediatrische patiënten met een lichaamsgewicht van 10kg of meer met paroxismale nachtelijke hemoglobinurie (PNH):- bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit.- bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab. ^IND

UM171 Vadadustat Voxelotor

Dexmedetomidine

Dostarlimab ^IND Mirvetuximab soravtansine

Bupivacaine extended release ^IND Buprenorphine ^IND Fasinumab Lidocaïne SDN037

Lotilaner

Abiraterone

Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT). - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is. - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. ^G Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. ^G

Darolutamide

Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT. ^IND

Degarelix ^IND Leuprolide mesylate Lutetium (177lu) vipivotide tetraxetan Masitinib Niraparib / abiraterone

Olaparib

Treatment in combination with abiraterone acetate in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). ^IND treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone ^IND

Pembrolizumab ^IND Relugolix

Anifrolumab Cyclobenzaprine hydrochloride Risankizumab ^IND Sarilumab ^IND

Secukinumab

Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. ^IND Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. ^IND

Tofacitinib ^IND Upadacitinib ^IND

Risdiplam

5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies. Extension of indication to include treatment of patients below 2 months of age. ^IND

Lumateperone

Darleukin fibromun Lenvatinib ^IND

Pembrolizumab

1L treatment with pembrolizumab for advanced melanoma, in combination with lenvatinib. ^IND Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, Stage IIC or stage III melanoma and to include the treatment of adolescents aged 12 years and older with advanced melanoma for Keytruda ^IND

Relatlimab

Abrocitinib Beremagene geperpavec Berkenschorsextract Deucravacitinib Difelikefalin

Dupilumab

Dupixent is geïndiceerd bij kinderen van 6 maanden tot 6 jaar met ernstige atopische dermatitis die in aanmerking komen voor systemische behandeling. ^IND Dupixent is geïndiceerd bij volwassenen voor de behandeling van Prurigo Nodularis die onvoldoende onder controle zijn met topische behandelingen, of wanneer deze behandelingen niet gepast zijn. ^IND

Lebrikizumab Ligelizumab Regenerative Skin Tissue Roflumilast topical Ruxolitinib phosphate Secukinumab ^IND Spesolimab

Tapinarof

Adult Plaque Psoriasis Atopische dermatitis

Tirbanibulin Tralokinumab ^IND

Daridorexant JZP-258 Natriumoxybaat controlled release Pitolisant

Brexucabtagene autoleucel Inolimomab Motixafortide Omidubicel Ruxolitinib ^IND Tabelecleucel Tisagenlecleucel-T ^IND Treosulfan ^IND

Nivolumab ^IND Ripretinib Trastuzumab deruxtecan ^IND Zolbetuximab

Cabozantinib ^IND

Pralsetinib

Gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with Tyrosine Kinase inhibitors and not previously treated with a RET inhibitor. Gavreto is indicated for the treatment of adults and pediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with Tyrosine kinase inhibitors and not previously treated with a RET inhibitor. ^IND

Selpercatinib

1L treatment advanced or metastatic RET fusion-positive thyroid cancer (TC) ^IND 1L treatment of adults and children >12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). ^IND

Axicabtagene ciloleucel ^IND Dapagliflozine ^IND Diazoxide choline (controlled-release tablet) Empagliflozine ^IND Levonorgestrel ^G Linzagolix Lonapegsomatropin Lumasiran Mirabegron ^IND Olopatadine / mometasone Osilodrostat Pirfenidone ^G Relugolix ^IND Relugolix / estradiol / norethisteronen Setmelanotide Sirolimus ^IND Sofpironium bromide Vosoritide

Bizalimogene ralaplasmid Bulevirtide Elbasvir / grazoprevir ^IND Glecaprevir / pibrentasvir ^IND Lonafarnib ^IND Maribavir Nirsevimab Remdesivir ^IND Sofosbuvir / velpatasvir ^IND Sofosbuvir / velpatasvir / voxilaprevi ^IND Tecovirimat

Published on 7 June 2022

ADHD

ALL

ALS

AML / MDS

Aggressive non-Hodgkin?s lymphoma

Ibrutinib

Antithrombotic medications

Asthma

Bacterial infections

Bladder cancer

Durvalumab

Bowel diseases

Upadacitinib

Brain cancer

Breast cancer

Palbociclib

Pembrolizumab

Trastuzumab deruxtecan

CLL

Acalabrutinib

Zanubrutinib

CML

COVID-19

Remdesivir

Tixagevimab / cilgavimab

Cervical cancer

Colon cancer

Cystic fibrosis

Elexacaftor / tezacaftor / ivacaftor

Dementia

Depression

Diabetes

Finerenon

Duchenne

Epilepsy

Eye disorders

Faricimab

Ranibizumab

Fungal infections

Posaconazol

HIV

Head and neck cancer

Headache

Hemostasis promoting medication

Indolent non-Hodgkin?s lymphoma

Infectious diseases other

Kidney cancer

Pembrolizumab

Lipid-lowering medications

Liver cancer

Durvalumab

Liver diseases

Lung cancer

Atezolizumab

Cemiplimab

Durvalumab

Lung diseases other

Mepolizumab

Mesothelioma

Metabolic diseases

Multiple Myeloma

Daratumumab

Isatuximab

Multiple sclerosis

Dimethyl fumarate

Teriflunomide

Muscular diseases other

Myeloproliferative disorders

Neuroendocrine cancer

Neurological disorders other

Oncology other

Lenvatinib

Nivolumab

Pembrolizumab

Other chronic immune diseases

Baricitinib

Other hematology

Other medication for cardiovascular diseases

Other metabolism and Endocrinology